140 related articles for article (PubMed ID: 36524437)
21. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
22. Intralesional Cidofovir application in recurrent laryngeal papillomatosis.
Pudszuhn A; Welzel C; Bloching M; Neumann K
Eur Arch Otorhinolaryngol; 2007 Jan; 264(1):63-70. PubMed ID: 17058091
[TBL] [Abstract][Full Text] [Related]
23. Spontaneous resolution of atopic dermatitis incidental to participation in benralizumab clinical trial for severe, uncontrolled asthma: a case report.
Pham DN
J Med Case Rep; 2021 Mar; 15(1):103. PubMed ID: 33673870
[TBL] [Abstract][Full Text] [Related]
24. Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma.
Chipps BE; Hirsch I; Trudo F; Alacqua M; Zangrilli JG
Ann Allergy Asthma Immunol; 2020 Jan; 124(1):79-86. PubMed ID: 31626906
[TBL] [Abstract][Full Text] [Related]
25. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials.
Tian BP; Zhang GS; Lou J; Zhou HB; Cui W
J Asthma; 2018 Sep; 55(9):956-965. PubMed ID: 29211545
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
29. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
30. Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia.
Isomoto K; Baba T; Sekine A; Aiko N; Ogura T
Intern Med; 2020 May; 59(9):1195-1198. PubMed ID: 32009090
[TBL] [Abstract][Full Text] [Related]
31. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Allen CT; Lee S; Norberg SM; Kovalovsky D; Ye H; Clavijo PE; Hu-Lieskovan S; Schlegel R; Schlom J; Strauss J; Gulley JL; Trepel J; Hinrichs CS
J Immunother Cancer; 2019 May; 7(1):119. PubMed ID: 31053174
[TBL] [Abstract][Full Text] [Related]
32. Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants.
Cheung TT; Mai TH; Chia YL; Yap DYH; Lee CH; Chen CC; Huang Y; Jin Y; Johnston J; Werkström V; Yao Y; Ge X; Zheng W
Drug Des Devel Ther; 2023; 17():209-218. PubMed ID: 36726737
[TBL] [Abstract][Full Text] [Related]
33. Benralizumab for the treatment of asthma.
Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
[TBL] [Abstract][Full Text] [Related]
34. High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab.
Watanabe S; Suzukawa M; Tashimo H; Ohshima N; Asari I; Imoto S; Kobayashi N; Tohma S; Nagase T; Ohta K
J Asthma; 2022 Aug; 59(8):1604-1612. PubMed ID: 34121592
[TBL] [Abstract][Full Text] [Related]
35. Stabilization of Recurrent Respiratory Papillomatosis with Pembrolizumab Therapy: A Case Report.
Strohl MP; Rosen CA
J Voice; 2023 Jul; 37(4):637.e1-637.e3. PubMed ID: 33992478
[TBL] [Abstract][Full Text] [Related]
36. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
[TBL] [Abstract][Full Text] [Related]
37. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
38. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study).
Martínez-Moragón E; García-Moguel I; Nuevo J; Resler G;
BMC Pulm Med; 2021 Dec; 21(1):417. PubMed ID: 34922515
[TBL] [Abstract][Full Text] [Related]
39. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
[TBL] [Abstract][Full Text] [Related]
40. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
